A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia | Zendy

Philip A. Kalra | Zendy; Sunil Bhandari | Zendy; Sanjiv Saxena | Zendy; Dhananjai Agarwal | Zendy; Georg Wirtz | Zendy; Josef Kletzmayr | Zendy; Lars L. Thomsen | Zendy; Daniel W. Coyne | Zendy

Open Access

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia

Author(s) -

Philip A. Kalra,

Sunil Bhandari,

Sanjiv Saxena,

Dhananjai Agarwal,

Georg Wirtz,

Josef Kletzmayr,

Lars L. Thomsen,

Daniel W. Coyne

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv293

Subject(s) - medicine , kidney disease , transferrin saturation , gastroenterology , iron deficiency , ferritin , dialysis , adverse effect , randomized controlled trial , anemia , bolus (digestion) , surgery

Iron deficiency anaemia is common in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and is often treated with oral or intravenous (IV) iron therapy. This trial compared the efficacy and safety of IV iron isomaltoside 1000 (Monofer®) and oral iron in NDD-CKD patients with renal-related anaemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research